| The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. | |
| | |
MedLine Citation:
|
PMID: 3106585 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We examined the possibility of continuing oxazaphosphorine therapy in patients with previously documented cyclophosphamide- or ifosfamide-induced hematuria by concomitant use of the uroprotective agent, mesna. Twenty-six patients with oxazaphosphorine-induced hematuria received additional cyclophosphamide or ifosfamide with mesna. Twelve, who had previously experienced hematuria with ifosfamide, received a median of 3.5 more cycles of ifosfamide/mesna. One patient developed further hematuria (grade 1). Of seven patients who experienced acute hematuria with cyclophosphamide, one experienced further hematuria after an additional course of cyclophosphamide with mesna, but none of the other six patients developed further hematuria when administered either cyclophosphamide/mesna (two) or ifosfamide/mesna (four). Seven patients who had chronic cyclophosphamide-induced hematuria had further oxazaphosphorine with mesna without worsening of their hematuria. Mesna is an effective uroprotective agent that prevents recurrent acute hemorrhagic cystitis, or worsening of chronic hemorrhagic cystitis, in patients receiving further oxazaphosphorine after previous ifosfamide- or cyclophosphamide-induced hematuria. |
| | |
Authors:
|
G L Andriole; J T Sandlund; J S Miser; V Arasi; M Linehan; I T Magrath |
Related Documents
:
|
18382155 - An evaluation of patient safety leadership walkarounds. 20661035 - Tracking data in the office environment. 18819295 - Hiv testing in dementia: clinical, ethical and patient safety implications. 15793345 - Crossing to safety: transforming healthcare organizations for patient safety. 22861125 - Assessment of nutritional status and meal-related situations among patients with chroni... 18179565 - The migraine cycle: patient burden of migraine during and between migraine attacks. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology Volume: 5 ISSN: 0732-183X ISO Abbreviation: J. Clin. Oncol. Publication Date: 1987 May |
Date Detail:
|
Created Date: 1987-06-19 Completed Date: 1987-06-19 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 8309333 Medline TA: J Clin Oncol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 799-803 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Child Child, Preschool Cyclophosphamide / adverse effects* Cystitis / prevention & control* Female Hematuria / chemically induced, prevention & control Hemorrhage / chemically induced* Humans Ifosfamide / adverse effects* Male Mercaptoethanol / analogs & derivatives* Mesna / therapeutic use* Neoplasms / drug therapy* |
| Chemical | |
Reg. No./Substance:
|
19767-45-4/Mesna; 3778-73-2/Ifosfamide; 50-18-0/Cyclophosphamide; 60-24-2/Mercaptoethanol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A phase I clinical trial of recombinant DNA gamma interferon.
Next Document: Changes in local cerebral glucose utilization induced by the beta-carbolines FG 7142 and DMCM reveal...